Business
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia. “The NTSAD Annual Family Conference is an important opportuni
About this update from Polaryx Therapeutics, Inc.
[{"type":"image","alt":"Polaryx Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Polaryx Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dphdMdM6dqfB6z52pG.7yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32","width":300,"height":50}},"lazy":false},{"type":"text","content":"PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia.","length":442,"tagName":"p"},{"type":"text","content":"“The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community,” said Alex Yang, J.D., LL.M., Chief Executive Officer of Polaryx Therapeutics. “These interactions are invaluable as we advance PLX-200 in a meaningful Phase 2 basket trial and our broader pipeline with the goal of delivering disease-modifying therapies for patients with significant unmet need.”","length":456,"tagName":"p"},{"type":"text","content":"The NTSAD Annual Family Conference is a leading gathering of patients, caregivers, clinicians, and researchers dedicated to advancing care and treatment for individuals affected by Tay-Sachs, Sandhoff disease, and related disorders. Polaryx will engage directly with the patient and advocacy community, share updates on its clinical development programs, and reinforce its commitment to advancing therapies for underserved pediatric populations.","length":445,"tagName":"p"},{"type":"text","content":"Polaryx’s lead program, PLX-200, is an oral small molecule designed to target multiple underlying disease mechanisms across several LSDs, including Sandhoff disease, and is being advanced through the SOTERIA Phase 2 basket trial evaluating multiple indications. Polaryx believes that active engagement with the patient community ...